Arcturus Therapeutics Files 8-K on Officer/Director Changes
Ticker: ARCT · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1768224
| Field | Detail |
|---|---|
| Company | Arcturus Therapeutics Holdings Inc. (ARCT) |
| Form Type | 8-K |
| Filed Date | Dec 15, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $219,580, b |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, director-changes, corporate-governance
Related Tickers: ARCT
TL;DR
Arcturus Therapeutics (ARCT) filed an 8-K detailing changes in its board and executive team.
AI Summary
Arcturus Therapeutics Holdings Inc. filed an 8-K on December 15, 2025, reporting events as of December 11, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in key personnel and officer appointments can signal strategic shifts or internal challenges that may affect the company's future performance.
Key Players & Entities
- Arcturus Therapeutics Holdings Inc. (company) — Registrant
- December 11, 2025 (date) — Earliest event reported
- December 15, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 10285 Science Center Drive, San Diego, California 92121 (address) — Principal executive offices
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with details on compensatory arrangements for these individuals.
When were the events reported in this 8-K filed?
The 8-K was filed on December 15, 2025, with the earliest event reported being on December 11, 2025.
What is the primary business of Arcturus Therapeutics Holdings Inc. according to the filing?
The company is classified under Pharmaceutical Preparations [2834].
Where are Arcturus Therapeutics' principal executive offices located?
The principal executive offices are located at 10285 Science Center Drive, San Diego, California 92121.
What other items are included in this 8-K filing besides personnel changes?
The filing also includes Financial Statements and Exhibits.
Filing Stats: 1,149 words · 5 min read · ~4 pages · Grade level 11.2 · Accepted 2025-12-15 08:30:40
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share ARCT The Nasdaq Stock Mar
- $219,580, b — Agreement provides for a base salary of $219,580, bonus eligibility equal to up to 20% of b
Filing Documents
- e665044_8k-arct.htm (8-K) — 30KB
- e665044_ex10-1.htm (EX-10.1) — 60KB
- e665044_ex10-2.htm (EX-10.2) — 17KB
- image1.jpg (GRAPHIC) — 13KB
- image_001.jpg (GRAPHIC) — 15KB
- 0001193805-25-001734.txt ( ) — 331KB
- arct-20251211.xsd (EX-101.SCH) — 3KB
- arct-20251211_lab.xml (EX-101.LAB) — 33KB
- arct-20251211_pre.xml (EX-101.PRE) — 22KB
- e665044_8k-arct_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 11, 2025, Arcturus Therapeutics Holdings, Inc., a Delaware corporation (the "Company") and Andy Sassine, Chief Financial Officer of the Company and a member of the Company's Board of Directors (the "Board"), mutually agreed to end their employment relationship in an amicable manner effective December 31, 2025 (the "Separation Date"). Mr. Sassine also stepped down as a member of the Board on December 11, 2025. Mr. Sassine indicated to the Company that his separation was not a result of any disagreement with the Company, the Board or the Company's management on any matter relating to the Company's operations, policies, or practices. In connection with his resignation, the Board decreased the size of the Board from nine members to eight members, effective immediately. On December 11, 2025, the Company entered into a Separation Agreement and General Release ("Separation Agreement") with Mr. Sassine (the "Separation Agreement"). Pursuant to the Separation Agreement, provided that Mr. Sassine complies with the terms of the Separation Agreement, including but not limited to the delivery of certain customary certifications and releases, Mr. Sassine shall be entitled to (i) a lump sum severance payment equal to 12 months of Mr. Sassine's base salary, (ii) bonus eligibility if and when paid to the Corporation's Chief Executive Officer in the manner described in the Agreement, (iii) reimbursement for certain attorney's fees, (iv) payment of up to 18 months of COBRA healthcare premium for Mr. Sassine and his dependents, and (v) and amendments to his existing stock options whereby (A) all unvested options to purchase shares of the Company's common stock held by Mr. Sassine shall accelerate and become immediately exercisable and (B) all stock options held by Mr. Sassine may be exercised for a 24-month period
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 10.1** Separation Agreement and General Release between Arcturus Therapeutics Holdings Inc. and Andy Sassine dated 11, 2025. 10.2 Employment Agreement between Arcturus Therapeutics Holdings Inc. and Joe Roberts dated July 3, 2018. 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document. ** Certain confidential portions of this exhibit have been redacted from the publicly filed document because such portions are (i) not material and (ii) would be competitively harmful if publicly disclosed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arcturus Therapeutics Holdings Inc. Date: December 15, 2025 By: /s/ Joseph E. Payne Name: Joseph E. Payne Title: Chief Executive Officer